H. Lundbeck A/S — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

6 Recruiting

7 Completed trials

18 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 4 Phase II: 2 Phase IV: 1 Phase I: 1 Phase I (Other): 4 Phase I (FiH): 1

Oversight events:

1 serious breach 1 urgent safety measure across 2 trials

View oversight register →

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Migraine 4 Medication overuse headache 1 Parkinson's disease 1 Multiple system atrophy 1

Top IMPs

EPTINEZUMAB 4 AG13909 1 AMLENETUG 1 HUMAN (SCFV)2-FAB FUSION PROTEIN AGAINST CD40L 1 LU AG09222 1

All trials

13 total

A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease Recruiting

2023-508693-29-00 Phase I (Other) 4 countries HUMAN (SCFV)2-FAB FUSION PROTEIN AGAINST CD40L
A trial to test the safety and tolerability of Lu AH70212 and Lu AH69593 in healthy adults. Recruiting

2025-522652-58-01 Phase I 1 country
A study to test the safety and tolerability of Lu AH69593 in adults that are healthy or have narcolepsy. Recruiting

2024-511073-29-00 Phase I (Other) 1 country
A Trial of Lu AG13909 in Adult Participants with Cushing’s Disease Recruiting

2023-504733-53-00 Phase II 6 countries AG13909
A study with eptinezumab in children and adolescents (6 to 17 years) with chronic or episodic migraine (REJOIN) Recruiting

2022-502917-27-00 Phase III 4 countries EPTINEZUMAB
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (PROSPECT-2) Recruiting

2024-510656-13-00 Phase III 4 countries EPTINEZUMAB
A trial of Lu AF82422 in Participants with Multiple System Atrophy (MSA) Ended

2024-517169-18-00 Phase III 5 countries AMLENETUG
A Trial of Lu AG13909 in Participants with Congenital Adrenal Hyperplasia Ended

2023-503711-15-00 Phase I (FiH) 6 countries
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Phase II 11 countries LU AG09222
Lu AF28996 in Patients With Parkinson's Disease Ended

2023-507785-12-00 Phase I (Other) 3 countries
A Trial Investigating the pain-relieving properties of Lu AG06474 in Healthy Adult Participants Ended

2023-503987-18-00 Phase I (Other) 1 country
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended

2024-510729-24-00 Phase IV 8 countries EPTINEZUMAB
Eptinezumab as Preventive Treatment of Migraine in Adults with Migraine Ended

2023-510183-12-00 Phase III 3 countries EPTINEZUMAB

Showing 1–13 of 13 trials

← All sponsors A–Z